aXichem expects increased sales of aXivite within dietary supplements in the US and EU over the next twelve months
aXichem AB (publ), which develops and markets natural analogue industrial chemicals, announces that it expects significantly increased sales over the next twelve months of the company's natural analogue product phenylcapsaicin in the area of dietary supplements and nutraceuticals, where the product is marketed under the brand name aXivite®. In the last two years, aXichem has built up a network of distributors in Europe and the USA and conducted studies that confirmed aXivite's positive effect in terms of weight control and physical training. The data has been presented in white papers and articles, which have been well received by manufacturers of dietary supplements and increased interest in aXivite. In the US, products with aXivite as an active ingredient have been launched at leading retailers such as GNC (General Nutrition Corporation) and Amazon. The company therefore assesses that continued positive development for aXivite can result in revenues of approximately SEK 20-25 million over the next twelve months.
“aXivite is marketed and sold by a highly professional network of distributors in the US and Europe. We have built up the market for this brand new product and so far have seen steadily increasing sales. aXichem today has the raw material to supply the demand we see and it will be very exciting to work further together with our distributors and continue to build the market for our unique product,” says Torsten Helsing, CEO of aXichem.
About phenylcapsaicin and aXivite
aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, connected by a triple bond. The result is an innovative natural analog capsaicin with high purity, which in several studies has been shown to have the same health-promoting properties, as well as some unique benefits, as natural capcaisin. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.
This information is such that aXichem AB is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person below, for publication on 7 February 2023, at 08:45 AM CET.
Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: [email protected]
aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, nutraceuticals and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Västra Hamnen Corporate Finance, www.vhcorp.se. Read more about aXichem at www.axichem.se
BBS-Bioactive Bone Substitutes Oyj:n varsinaisen yhtiökokouksen 2023 päätökset
BBS-Bioactive Bone Substitutes Oyj:n varsinainen yhtiökokous pidettiin torstaina 30.3.2023 alkaen kello 14.00 Oulussa.Yhtiökokous vahvisti yhtiön tilinpäätöksen tilikaudelta 2022 sekä myönsi vastuuvapauden hallituksen jäsenille ja toimitusjohtajalle.Yhtiökokous päätti hallituksen ehdotuksen mukaises...
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2023
The maximum number of shares to be issued pursuant to the authorization shall not exceed 6,000,000 shares.The Board of Directors decides on all terms and conditions for issuing shares, options and other special rights entitling to shares. Share issues and the issuance of option rights and other spec...
Cyxone meddelar valberedningens förslag inför årsstämma samt två ledamöters utträde, och förändrade förutsättningar kring styrelsens beslutsmässighet
Cyxone (publ) meddelar att valberedningen för Cyxone AB presenterar sitt förslag till beslut på årsstämman avseende val av styrelseledamöter och styrelseordförande. Två ledamöter, Theresa Comiskey Olsen och Saad Gilani, har valt att avgå på egen begäran per den 31 mars. Denna förändring i styrelsens...
Resolutions of the Annual General Meeting of Curasight A/S
Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to i...